Table 2 Clinical and laboratory parameters in LC group and non-LC group
Clinical and laboratory parameters | LC group (n = 19) | Non-LC group (n = 3) | P |
|---|---|---|---|
Age | 57.4 ± 9.9 | 63.0 ± 7.6 | 0.361 |
Sex | 0.273 | ||
Male (%) | 11 (57.9) | 3 (100) | |
Female (%) | 8 (42.1) | 0 (0) | |
Drug duration (days) | 13.2 ± 8.6 | 18.7 ± 10.5 | 0.328 |
Drug total dose (mg) | 3831.6 ± 2513.8 | 5600.0 ± 3152.2 | 0.284 |
WBC (× 103/uL) | 6.2 ± 3.4 | 12.0 ± 1.6 | 0.009 |
CK (U/L) | 21,132.1 ± 16,865.7 | 20,930.0 ± 9363.7 | 0.984 |
LDH (U/L) | 2416.1 ± 1578.6 | 1716.0 ± 753.2 | 0.466 |
AST (U/L) | 1088.3 ± 638.2 | 1403.5 ± 748.8 | 0.518 |
ALT (U/L) | 374.5 ± 244.2 | 467.5 ± 105.4 | 0.606 |
Albumin (g/dL) | 2.7 ± 0.5 | 3.5 ± 0.8 | 0.034 |
BUN (mg/dL) | 26.5 ± 22.9 | 50.6 ± 40.9 | 0.141 |
Creatinine (mg/dL) | 1.6 ± 1.8 | 3.9 ± 3.5 | 0.075 |
Sodium (mmol/L) | 134.9 ± 6.5 | 140.3 ± 4.7 | 0.186 |
Potassium (mmol/L) | 4.5 ± 0.7 | 4.9 ± 0.7 | 0.336 |
Hospital days | 24.0 ± 9.5 | 11.0 ± 5.6 | 0.081 |
Clinical signs and symptoms | |||
Muscle pain (%) | 17 (89.5) | 3 (100) | 1.000 |
Muscle weakness (%) | 8 (42.1) | 1 (33.3) | 1.000 |
Oliguria (%) | 2 (10.5) | 2 (66.7) | 0.371 |
Dark urine (%) | 2 (10.5) | 1 (33.3) | 0.073 |
DM (%) | 1 (5.2) | 0 | 1.000 |
ARF (%) | 5 (26.3) | 2 (66.7) | 0.227 |
Death (%) | 4 (21.1) | 0 (0) | 0.603 |
Child-Pugh classification | |||
A (%) | 3 (15.8) | NA | |
B (%) | 7 (36.8) | NA | |
C (%) | 9 (47.4) | NA | |
Etiology of LC | NA | ||
Hepatitis B (%) | 12 (63.2) | NA | |
Hepatitis C (%) | 2 (10.5) | NA | |
Alcohol (%) | 4 (21.1) | NA | |
Cryptogenic (%) | 1 (5.2) | NA | |